Boston Scientific Earlier Disclosed That On Apr. 3, Co. And Axonics Received Request For Additional Information From FTC In Connection With FTC's Merger Review; Says The Merger Is Now Expected To Be Completed In The Second Half Of 2024

4/4/24 8:55:38 AM ET

$AXNX

$BSX

Medical/Dental Instruments

Health Care

Medical/Dental Instruments

Health Care

Get the next $AXNX alert in real time by email

Boston Scientific Earlier Disclosed That On Apr. 3, Co. And Axonics Received Request For Additional Information From FTC In Connection With FTC's Merger Review; Says The Merger Is Now Expected To Be Completed In The Second Half Of 2024

Get the next $AXNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AXNX
$BSX

Company	Date	Price Target	Rating	Analyst
Boston Scientific Corporation $BSX	10/18/2024		Buy → Hold	Needham
Boston Scientific Corporation $BSX	5/30/2024	$90.00	Buy	Goldman
Boston Scientific Corporation $BSX	2/1/2024	$65.00 → $80.00	Neutral → Buy	Mizuho
Axonics Inc. $AXNX	1/9/2024		Outperform → Peer Perform	Wolfe Research
Boston Scientific Corporation $BSX	7/19/2023	$59.00	Outperform	Robert W. Baird
Axonics Inc. $AXNX	7/19/2023	$69.00	Outperform	Robert W. Baird
Axonics Inc. $AXNX	7/13/2023	$70.00	Overweight	KeyBanc Capital Markets
Boston Scientific Corporation $BSX	6/30/2023	$64.00	Buy	CL King

More analyst ratings

$AXNX
$BSX
Press Releases

Fastest customizable press release news feed in the world

Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablatio
11/16/24 3:07:00 PM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Closes Acquisition of Axonics, Inc.
MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti
11/15/24 8:43:00 AM ET
$AXNX
$BSX
Medical/Dental Instruments
Health Care
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi
11/14/24 9:30:00 AM ET
$BSX
Medical/Dental Instruments
Health Care

$AXNX
$BSX
Financials

Live finance-specific insights

Boston Scientific Announces Results for Third Quarter 2024
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
10/23/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.
10/2/24 8:00:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Announces Results for Second Quarter 2024
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.
7/24/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi
11/14/24 9:30:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors
Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer
7/25/24 8:00:00 AM ET
$AXNX
Medical/Dental Instruments
Health Care
BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors
BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.
12/27/23 8:00:00 AM ET
$AXNX
Medical/Dental Instruments
Health Care

Boston Scientific Earlier Disclosed That On Apr. 3, Co. And Axonics Received Request For Additional Information From FTC In Connection With FTC's Merger Review; Says The Merger Is Now Expected To Be Completed In The Second Half Of 2024

Chat with this insight

Recent Analyst Ratings for $AXNX$BSX

$AXNX$BSX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

March 1, 2024 - FDA Roundup: March 1, 2024

$AXNX$BSX SEC Filings

SEC Form EFFECT filed by Axonics Inc.

Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 25-NSE filed by Axonics Inc.

$AXNX$BSX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Boston Scientific downgraded by Needham

Goldman initiated coverage on Boston Scientific with a new price target

Boston Scientific upgraded by Mizuho with a new price target

$AXNX$BSX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)

EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)

Director Snyderman Nancy Lynn Md returned $1,061,024 worth of shares to the company (14,944 units at $71.00), closing all direct ownership in the company (SEC Form 4)

$AXNX$BSX Press Releases

Fastest customizable press release news feed in the world

Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial

Boston Scientific Closes Acquisition of Axonics, Inc.

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

$AXNX$BSX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

$AXNX$BSX Market Insights

Live Market Insights

Apple To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $85

Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $88

$AXNX$BSX Financials

Live finance-specific insights

Boston Scientific Announces Results for Third Quarter 2024

Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results

Boston Scientific Announces Results for Second Quarter 2024

$AXNX$BSX Leadership Updates

Live Leadership Updates

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

Recent Analyst Ratings for
$AXNX
$BSX

$AXNX
$BSX
FDA approvals

$AXNX
$BSX
SEC Filings

$AXNX
$BSX
Analyst Ratings

$AXNX
$BSX
Insider Trading

$AXNX
$BSX
Press Releases

$AXNX
$BSX
Large Ownership Changes

$AXNX
$BSX
Market Insights

$AXNX
$BSX
Financials

$AXNX
$BSX
Leadership Updates